You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antisense oligonucleotide

Showing 1 - 25 of 208
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Tumors Trial in Houston (BP1001-A (Liposomal Grb2 Antisense

Not yet recruiting
  • Solid Tumor, Adult
  • +5 more
  • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)
  • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
  • (no location specified)
Jun 7, 2022

Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) Trial in Augusta, Nashville, Houston

Recruiting
  • Mantle Cell Lymphoma
  • +9 more
  • L-Bcl-2 antisense oligonucleotide
  • Augusta, Georgia
  • +2 more
Nov 18, 2022

Pancreatic Ductal Adenocarcinoma Trial (OT-101, FOLFIRINOX)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • (no location specified)
Oct 5, 2023

Antisense Oligonucleotide for Spinal Muscular Atrophy

Recruiting
  • Spinal Muscular Atrophy
  • Beijing, Beijing, China
  • +2 more
Jan 11, 2022

Advanced Solid Tumors Trial (WGI-0301)

Not yet recruiting
  • Advanced Solid Tumors
  • (no location specified)
Jul 11, 2022

Rheumatoid Arthritis Trial in Canada, United States (ISIS 104838)

Completed
  • Rheumatoid Arthritis
  • ISIS 104838
  • Birmingham, Alabama
  • +30 more
Dec 1, 2022

Healthy Participants Trial in Toronto (IONIS FXI-LRx, Placebo)

Completed
  • Healthy Participants
  • IONIS FXI-LRx
  • Placebo
  • Toronto, Ontario, Canada
    BioPharma Services Inc.
Jan 13, 2022

Prostate Cancer Trial in Ann Arbor, Detroit (ARRx, Enzalutamide)

Suspended
  • Prostate Cancer
  • Ann Arbor, Michigan
  • +1 more
Dec 17, 2021

Amyloidosis Trial in Boston (Inotersen)

Active, not recruiting
  • Amyloidosis
  • Boston, Massachusetts
    Brigham and Women's Hospital
Dec 3, 2020

Retinitis Pigmentosa, Usher Syndrome Type 2 Trial in Canada, France, United States (RNA antisense oligonucleotide for

Terminated
Has Results
  • Retinitis Pigmentosa
  • Usher Syndrome Type 2
  • RNA antisense oligonucleotide for intravitreal injection
  • Boston, Massachusetts
  • +6 more
Dec 12, 2022

Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Dallas, Madison, London (QR-421a, Sham-procedure)

Active, not recruiting
  • Retinitis Pigmentosa
  • +7 more
  • Dallas, Texas
  • +2 more
Apr 21, 2022

Progressive Supranuclear Palsy (PSP) Trial in Worldwide (antisense oligonucleotide, )

Recruiting
  • Progressive Supranuclear Palsy (PSP)
  • antisense oligonucleotide
  • placebo
  • La Jolla, California
  • +11 more
Feb 23, 2022

Acute Myeloid Leukemia (AML) Trial in United States (BP1001 in combination with Ventoclax plus decitabine, BP1001 plus

Recruiting
  • Acute Myeloid Leukemia (AML)
  • BP1001 in combination with Ventoclax plus decitabine
  • BP1001 plus decitabine
  • Fairway, Kansas
  • +5 more
Jan 3, 2022

Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Canada, France, United States (QR-421a, Sham-procedure (dose

Completed
  • Retinitis Pigmentosa
  • +7 more
  • QR-421a
  • Sham-procedure (dose cohort 1&2 only)
  • Boston, Massachusetts
  • +6 more
Apr 19, 2022

Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Worldwide (Ultevursen, Sham-procedure)

Recruiting
  • Retinitis Pigmentosa
  • +7 more
  • San Diego, California
  • +14 more
Jul 29, 2022

Dravet Syndrome Trial in United States (STK-001 - Single Ascending Doses, STK-001 - Multiple Ascending Doses)

Recruiting
  • Dravet Syndrome
  • STK-001 - Single Ascending Doses
  • STK-001 - Multiple Ascending Doses
  • San Francisco, California
  • +17 more
Feb 17, 2022

Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome Trial in Houston (BP1001, BP1001

Completed
  • Recurrent Adult Acute Myeloid Leukemia
  • +3 more
  • BP1001
  • BP1001 in combination with LDAC
  • Houston, Texas
    M. D. Anderson Cancer Center
May 26, 2020

Glioblastoma Multiforme, Glioblastoma Trial in United States (biological, procedure, drug)

Not yet recruiting
  • Glioblastoma Multiforme
  • Glioblastoma
  • IGV-001 Cell Immunotherapy
  • +3 more
  • Newark, Delaware
  • +22 more
Jun 24, 2022

Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (BP1001 (varying

Withdrawn
  • Chronic Myelogenous Leukemia, Ph1-Positive
  • +2 more
  • BP1001 (varying dose)
  • +2 more
  • Houston, Texas
    The University of Texas M.D. Anderson Cancer Center
May 26, 2020

Healthy Subjects, Cystic Fibrosis Trial in Germany, United Kingdom (IONIS-ENaCRx, Placebo)

Completed
  • Healthy Subjects
  • Cystic Fibrosis
  • Essen, Germany
  • +7 more
Feb 2, 2021

Bladder Cancer, Breast Cancer, Kidney Cancer Trial (custirsen sodium, docetaxel, pharmacological study)

Completed
  • Bladder Cancer
  • +6 more
  • custirsen sodium
  • +2 more
  • (no location specified)
Apr 6, 2020

Prostate Cancer Trial in Vancouver (buserelin, custirsen sodium, flutamide)

Completed
  • Prostate Cancer
  • Vancouver, British Columbia, Canada
    British Columbia Cancer Agency - Vancouver Cancer Centre
Apr 6, 2020

Covid19 Trial in Rio De Janeiro, São Paulo (ISIS 721744, Normal Saline)

Completed
  • Covid19
  • ISIS 721744
  • Normal Saline
  • Rio De Janeiro, Brazil
  • +2 more
Sep 21, 2022

Natural History of Pompe Disease

Recruiting
  • Glycogen Storage Disease Type II, Adult
    • Garches, Hauts-de-Seine, France
      Hôpital Raymond Poincaré
    Apr 20, 2022

    Heathy Participants Trial (AZD7053, Placebo)

    Not yet recruiting
    • Heathy Participants
    • (no location specified)
    Oct 19, 2023